FDA Greenlights Easier Path for Scar-Reducing Light Therapy Devices
Published Date: 5/1/2026
Rule
Summary
The FDA is officially classifying phototherapy devices that help reduce the look of fresh surgical cuts as Class II, meaning they have special safety rules but are easier to get to patients. This change, effective May 1, 2026, makes it safer and simpler for companies to offer these devices without the toughest regulations. Patients and makers both win with better access and less red tape!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Device moved to Class II, easier market access
The FDA officially classified phototherapy devices for reducing the appearance of acute post-surgical incisions as Class II (special controls), effective May 1, 2026, with the classification applicable December 3, 2021. This puts the device in a lower regulatory class than automatic Class III and lets sponsors rely on the De Novo/510(k) pathway and enables the device to serve as a predicate for future 510(k) devices.
Manufacturers must meet special testing and labeling
To fall within Class II, manufacturers must meet special controls including non-clinical performance testing (spectrum and power verification, heat dissipation, biophotonic properties), biocompatibility and sterility testing, shelf-life demonstration for the photoconverter gel, electromagnetic/electrical/thermal safety testing, software verification/validation and hazard analysis, and specific labeling (technical specs, eye-safety warnings, and gel shelf life). These requirements are codified at 21 CFR 878.4880.
Patients may see improved access to device
FDA states that classifying these phototherapy devices into Class II will enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens. The final order is effective May 1, 2026, and the device type was classified December 3, 2021.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2026-08494, Small Business Lending Under the Equal Credit Opportunity Act (Regulation B)
Starting June 30, 2026, new rules will help banks and lenders better track loans to small, women-owned, and minority-owned businesses. These changes make it easier for lenders to follow the rules, improve the quality of loan data, and support fair lending. Lenders must fully comply by January 1, 2028, so small businesses get a fair shot at credit.
Next: 2026-08515, Overweight and Oversize Items Fee Application
Starting July 12, 2026, the Postal Service will charge a $200 fee for overweight or oversize items found in the mail system or reported in shipping manifests. This fee applies to both retail and commercial mailers, except for items caught and returned during retail transactions. Mailers must pay the fee before their item is released, so watch your package size and weight!